MannKind Corporation
MannKind Corporation develops and commercializes inhaled therapeutic products for endocrine and orphan lung diseases. Products include Afrezza, V-Go, Tyvaso DPI, MNKD-101, and MNKD-201. The company has agreements with United Therapeutics, Vertice Pharma, Thirona, Biomm S.A., and Cipla Ltd. MannKind is headquartered in Danbury, Connecticut, and was incorporated in 1991.
Overview
Strengths
- Consistent growth: revenue has compounded at 39.9% a year over 5 years, rising every year.
- Earnings are projected to grow at a solid rate (20.0% per year).
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 6.0%) has been below its cost of capital of 8.5% in 3 of the last 4 years.
- Unreliable cash generation: free cash flow was negative in 4 of the last 6 years.
- High leverage: net debt is 4.3x EBITDA, against a median of 0.5x for its Biotechnology peers.
- Heavy interest burden: interest expense absorbs 96% of operating profit.
- Our discounted cash flow target price (0.82 USD) is 78% below the current price.
- Unstable profitability: operating margin ranged from -71% to 24% over the last 6 years, with operating losses in 3 of them.
Key Financial Data